Microdosing: A critical assessment of human data

Journal of Pharmaceutical Sciences

Volumn 101, Issue 11, 2012, Pages 4067-4074

  Rowland, Malcolm ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bioavailability; Biopharmaceutical drug disposition classification system (BDDCS); Oral absorption; PET; Pharmacokinetics; Physiological model

Indexed keywords

ANTIESTROGEN; ATENOLOL; CAFFEINE; CELIPROLOL; CLARITHROMYCIN; CYCLOSPORIN; DIAZEPAM; DIPHENHYDRAMINE; ENALAPRIL; FEXOFENADINE; LEVOFLOXACIN; LOSARTAN; METFORMIN; MIDAZOLAM; PARACETAMOL; PHENOBARBITAL; PROPAFENONE; QUINIDINE; SUMATRIPTAN; TELMISARTAN; TOLBUTAMIDE; UNCLASSIFIED DRUG; VERAPAMIL; WARFARIN; ZIDOVUDINE; ZK 253;

AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CLINICAL RESEARCH; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG FORMULATION; DRUG INDUSTRY; DRUG MICRODOSE; HUMAN; MAXIMUM PLASMA CONCENTRATION; MICRODOSIMETRY; NONHUMAN; PROTEIN BINDING;

EID: 84866346071     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23290     Document Type: Article

References (41)

1. Lappin G, Garner RC. 2003. Big physics, small doses: The use of AMS and PET in human microdosing of development drugs. Nat Rev Drug Discov 2:233-240.
2. Lappin G, Garner RC. 2008. The utility of microdosing over the past 5 years. Expert Opin Drug Metab Toxicol 4:1499-1506.
3. Sugiyama Y, Yamashita S. 2011. Impact of microdosing clinical study-Why necessary and how useful? Adv Drug Deliv Rev 63:494-502.
4. Beaumont K, Smith DA. 2009. Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research? Curr Opin Drug Discov Dev 12:61-71.
5. Vuppugalla R, Marathe P, He HD, Jones RD, Yates JW, Jones HM, Gibson CR, Chien JY, Ring BJ, Adkison KK, Ku MS, Fischer V, Dutta S, Sinha VK, Björnsson T, Lavé T, Poulin P. 2011. PHRMA CPCDC Initiative on predictive models of human pharmacokinetics, part 4: Prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the wajima approach. J Pharm Sci 100:4111-4126.
6. Muller PY. 2011. Comparative requirements for exploratory clinical trials-eIND, eCTA, and microdosing. Adv Drug Deliv Rev 63:511-517.
7. 2008. Guidance. In Microdose clinical studies. Tokyo, Japan: Ministry of Health, Labor and Welfare, Pharmaceutical and Medical Safety Bureau.
8. EMEA. 2009. In ICH topic M3: Note for guidance on non-clinical safety pharmacology studies for human pharmaceuticals CPMP/ICH/286/95. London, UK: EMEA.
9. Kola I, Landis J. 2004. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711-715.
10. Morgan P, Van Der Graaf PH, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, Street SDA. 2012. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov Today 17:419-424.
11. Lappin G, Kuhnz W, Jochemsen R, Kneer J, Chaudhary A, Oosterhuis B, Drijfhout WJ, Rowland M, Garner RC. 2006. Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugs. Clin Pharmacol Ther 80:203-215.
12. Lappin G, Shishikura Y, Jochemsen R, Weaver RJ, Gesson C, Houston JB, Oosterhuis B, Bjerrum OJ, Rowland M, Garner RC. 2010. Pharmacokinetics of fexofenadine: Evaluation of a microdose and assessment of absolute oral bioavailability. Eur J Pharm Sci 40:125-131.
13. Lappin G, Shishikura Y, Jochemsen R, Weaver RJ, Gesson C, Houston JB, Oosterhuis B, Bjerrum OJ, Grynkiewicz G, Alder J, Rowland M, Garner C. 2011. Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers. Eur J Pharm Sci 43:141-150.
14. Wagner CC, Simpson M, Zeitlinger M, Bauer M, Karch R, Abrahim A, Feurstein T, Schuetz M, Kletter K, Mueller M, Lappin G, Langer O. 2011. A combined accelerator mass spectrometry-positron emission tomography human microdose study with (14)C- and (11)C-labelled verapamil. Clin Pharmacokinet 50:111-120.
15. Vuong LT, Ruckle JL, Blood AB, Reid MJ, Wasnich RD, Synal H, Dueker SR. 2008. Use of accelerator mass spectrometry to measure the pharmacokinetics and peripheral blood mononuclear cell concentrations of zidovudine. J Pharm Sci 97:2833-2843.
16. Madan A, O'Brien Z, Wen J, O'Brien C, Farber RH, Beaton G, Crowe P, Oosterhuis B, Garner RC, Lappin G, Bozigian HP. 2009. A pharmacokinetic evaluation of five H(1) antagonists after an oral and intravenous microdose to human subjects. Br J Clin Pharmacol 67:288-298.
17. Mahajan R, Parvez A, Gupta K. 2009. Microdosing vs. therapeutic dosing for evaluation of pharmacokinetic data: A comparative study. J Young Pharmacists 1:290-294.
18. Chiyoda T, Kobayashi T, Inano A, Nozawa K, Yatsu M, Tozuka Z, Matui T, Hamabe Y, Ikushima I, Kaji Y, Irie S, Ikeda T, Sugiyama Y. 2010. Microdose clinical study using 14C-labeled acetaminophen to detect pharmacokinetic alternations by inhibition of its metabolic pathway. Clin Pharm Ther 87:S92-S92.
19. Tozuka Z, Kusuhara H, Nozawa K, Hamabe Y, Ikushima I, Ikeda T, Sugiyama Y. 2010. Microdose study of (14)C-acetaminophen with accelerator mass spectrometry to examine pharmacokinetics of parent drug and metabolites in healthy subjects. Clin Pharm Ther 88:824-830.
20. Yamazaki A, Kumagai Y, Yamane N, Tozuka Z, Sugiyama Y, Fujita T, Yokota S, Maeda M. 2010. Microdose study of a P-glycoprotein substrate, fexofenadine, using a non-radioisotope-labelled drug and LC/MS/MS. J Clin Pharm Ther 35:169-175.
21. Croft M, Keely B, Morris I, Tann L, Lappin G. 2012. Predicting drug candidate victims of drug-drug interactions, using microdosing. Clin Pharmacokinet 51:237-246.
22. Lim MS, Seong SJ, Park J, Seo JJ, Lee J, Yu K, Lee HW, Yoon Y. 2012. Assessment of pharmacokinetic proportionality of levofloxacin and cyclosporine over a 100-fold dose range in healthy human volunteers. Expert Opin Drug Metab Toxicol 8:399-405.
23. Kusuhara H, Ito S, Kumagai Y, Jiang M, Shiroshita T, Moriyama Y, Inoue K, Yuasa H, Sugiyama Y. 2011. Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin Pharm Ther 89:837-844.
24. Ieiri I, Nishimura C, Maeda K, Sasaki T, Kimura M, et al. 2011. Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose. Pharmacogenet Genomics 21:495-505.
25. Maeda K, Takano J, Ikeda Y, Fujita T, Oyama Y, Nozawa K, Kumagai Y, Sugiyama Y. 2011. Nonlinear pharmacokinetics of oral quinidine and verapamil in healthy subjects: A clinical microdosing study. Clin Pharm Ther 90:263-270.
26. Ieiri I, Doi Y, Maeda K, Sasaki T, Kimura M, Hirota T, Chiyoda T, Miyagawa M, Irie S, Iwasaki K, Sugiyama Y. 2012. Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose. J Clin Pharmacol 52:1078-1079.
27. Benet LZ, Broccatelli F, Oprea TI. 2011. BDDCS applied to over 900 drugs. AAPS J 13:519-547.
28. Mager DE, Jusko WJ. 2001. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharm Pharmacodyn 28:507-532.
29. m values. Pharm Res 29:651-668.
30. Kaplan N, Flanner H, Hafkin B. 2009. Correlation of AFN-1252 phase 0 microdosing and phase 1 pharmacokinetics. In Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2009; San Francisco, California; 49:207.
31. Wang JL, Aston K, Limburg D, Ludwig C, Hallinan AE, Koszyk F, Hamper B, Brown D, Graneto M, Talley J, Maziasz T, Masferrer J, Carter J. 2010. The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part III: The three microdose candidates. Bioorg Med Chem Lett 20:7164-7168.
32. Zhou XJ, Garner RC, Nicholson S, Kissling CJ, Mayers D. 2009. Microdose pharmacokinetics of IDX899 and IDX989, candidate HIV-1 non-nucleoside reverse transcriptase inhibitors, following oral and intravenous administration in healthy male subjects. J Clin Pharm 49:1408-1416.
33. Zhou XJ, Pietropaolo K, Damphousse D, Belanger B, Chen J, Sullivan-Bolyai J, Mayers D. 2009. Single-dose escalation and multiple-dose safety, tolerability, and pharmacokinetics of IDX899, a candidate human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor, in healthy subjects. Antimicrob Agents Chemother 53:1739-1746.
34. Thomas AT, Ognibene T, Daley P, Turteltaub K, Radousky H, Bench G. 2011. Ultrahigh efficiency moving wire combustion interface for online coupling of high-performance liquid chromatography (HPLC). Anal Chem 83:9413-9417.
35. Gueorguieva I, Rowland M. Is pharmacokinetic variability in microdose and therpeautic dose trials comparable? AAPS J, submitted for publication.
36. Rowland M, Peck C, Tucker G. 2011. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharm Toxicol 51:45-73.
37. Jones HM, Gardner IB, Collard WT, Stanley PJ, Oxley P, Hosea NA, Plowchalk D, Gernhardt S, Lin J, Dickins M, Rahavendran SR, Jones BC, Watson KJ, Pertinez H, Kumar V, Cole S. 2011. Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling. Clin Pharmacokinet 50:331-347.
38. Maeda K, Ikeda Y, Fujita T, Yoshida K, Azuma Y, Haruyama Y, Yamane N, Kumagai Y, Sugiyama Y. 2011. Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clin Pharm Ther 90:575-581.
39. Lesko LJ, Rowland M, Peck CC, Blaschke TF. 2000. Optimizing the science of drug development: Opportunities for better candidate selection and accelerated evaluation in humans. Pharm Res 17:1335-1344.
40. Goto M, Masuda S, Saito H, Uemoto S, Kiuchi T, Tanaka K, Inui K. 2002. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 12:451-457.
41. Wang S, Zhang H, Malfatti M, White RdV, Lara PN, Jr., Turteltaub K, Henderson P, Pan C. 2010. Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells. Chem Res Toxicol 23:1653-1655.